Skip to main content
. Author manuscript; available in PMC: 2009 Feb 1.
Published in final edited form as: Antiviral Res. 2007 Oct 8;77(2):153–156. doi: 10.1016/j.antiviral.2007.09.005

Fig 3.

Fig 3

Entry of the LASV-MLV pseudotype is inhibited in genistein-treated cells. Genistein-treated and untreated Vero cells were incubated with LASV-MLV pseudotypes for 48 h. After the incubation, the cells were fixed with an X-gal stain containing: 0.05 M potassium ferrocyanide and potassium ferricyanide, 2 mM X-gal, and PBS. β-gal expressing cells were counted and expressed as colony forming units/ml (CFU/ml). (A) Vero cells were treated with various concentrations of genistein for 1 h and infected with the LASV-MLV pseudotype. (B) Vero cells were treated with 100 μM of genistein or 0.1% DMSO and transduced with the LASV-MLV pseudotype. An asterisk represents a p<0.05 as determined by a Student’s t-test.